Health Care • Biotechnology: Pharmaceutical Preparations
$0.86 ▼ -0.02
(-2.73%)
MKT CAP: $11.5M • VOL: 111.9K
52W L $1 52W H $6
ROARABLE / RQD
E • 32/100
PIOTROSKI
2 / 9
TVRD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $7.1M | $21.0M |
| YoY Revenue Growth % | — | -66.0% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$26.7M | -$28.1M | -$121.5M |
| Operating Margin % | — | -80.0% | -80.0% |
| Net Income (GAAP) | -$18.2M | -$29.4M | -$11.8M |
| EBITDA (Normalized) | — | -$27.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$23.5M | -$18.3M | -$92.1M |
| Capital Expenditures (CapEx) | — | $1.0M | — |
| Free Cash Flow (FCF) | -$23.5M | -$19.4M | -$92.1M |
| FCF Margin % | — | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $20.7M | $31.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $20.9M | -$91.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR TVRD.